Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
1.430
+0.080 (5.93%)
At close: Aug 13, 2025, 4:00 PM
1.410
-0.020 (-1.40%)
Pre-market: Aug 14, 2025, 4:37 AM EDT

Company Description

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.

It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.

The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation
Geron logo
CountryUnited States
Founded1990
IPO DateJun 30, 1996
IndustryBiotechnology
SectorHealthcare
Employees229
CEOHarout Semerjian

Contact Details

Address:
919 East Hillsdale Boulevard, Suite 250
Foster City, California 94404
United States
Phone650 473 7700
Websitegeron.com

Stock Details

Ticker SymbolGERN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000886744
CUSIP Number374163103
ISIN NumberUS3741631036
Employer ID75-2287752
SIC Code2834

Key Executives

NamePosition
Harout SemerjianChief Executive Officer, President and Director
Michelle J. RobertsonExecutive Vice President, Chief Financial Officer, Treasurer and Principal Financial and Accounting Officer
Dr. Andrew J. Grethlein Ph.D.Executive Vice President and Chief Operating Officer
James Ziegler M.B.A.Executive Vice President and Chief Commercial Officer
Dr. Joseph Emile Eid M.D.Executive Vice President of Research and Development
Aron FeingoldVice President of Investor Relations and Corporate Communications
Scott SamuelsExecutive Vice President, Chief Legal Officer and Secretary
Shannon T. OdamExecutive Vice President and Chief People Officer

Latest SEC Filings

DateTypeTitle
Aug 6, 2025S-8Securities to be offered to employees in employee benefit plans
Aug 6, 20258-KCurrent Report
Aug 6, 202510-QQuarterly Report
Aug 6, 20258-KCurrent Report
Jun 30, 2025S-8Securities to be offered to employees in employee benefit plans
May 27, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 7, 202510-QQuarterly Report
May 7, 20258-KCurrent Report
Apr 8, 2025ARSFiling